Precision swings to profit. Precision BioSciences reported GAAP diluted EPS of $1.05 for Q4 2025, a dramatic reversal from the year-ago loss of $2.22 per share. The biotech posted net income of $20.1 million, compared to a loss last year. The swing from loss to profitability represents a fundamental shift in the company’s financial trajectory.
Revenue holds flat sequentially. The company generated $34.2 million in revenue. For a biotechnology company, the path to sustained profitability typically requires either expanding partnership revenue or advancing clinical programs toward commercialization. The stock traded at $5.35 with volume of 236,044 shares, showing muted reaction to the results.
Historical context matters. The Q4 profit stands in sharp contrast to Precision’s recent history: the company posted losses in the three prior quarters. Investors will need to determine whether this marks a sustainable inflection point or a temporary boost from non-recurring items.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.